Retour

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

stocks Product / Services Announcement

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.

GlobeNewswire Inc. • 23/10/2023 à 22:01:00
Author • Mereo BioPharma Group plc
Mereo BioPharma Group plc American Depositary Shares
Adresse: ONE CAVENDISH PLACE
Code postal: W1G0QF
Ville: LONDON
Region: X0
Numéro de telephone: 4403330237300
Site internet: https://www.mereobiopharma.com
Status: Active
Info de l'entreprise

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Date de référencement2018-04-24
MarchéStocks
LocaleUS
Echange principalXNAS
TypeADRC
DeviseUSD
CIK0001719714
Composite figiBBG00KFWZC67
Share Class figiBBG00KFWZCX7
Market Cap671,566,259 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employés33
Share Class Shares Outstanding769260000
Weighted Shares Outstanding153852522
Round Lot100
Date de mise à jour2024-09-19
Stats
5 derniers jours
19-09
18-09
17-09
16-09
13-09
Dernier
4.5
4.15
3.97
4.49
4.295
Variation
8.12%
4.53%
-11.74%
4.54%
-3.22%
Ouverture
4.162
3.97
4.498
4.295
4.438
Plus haut
4.5
4.299
4.57
4.56
4.438
Plus bas
4.433
4.295
4.56
4.56
4.405
Historique
PériodeVarPlus hautPlus bas
1 semaine
1.4%
4.438
4.295
1 mois
1.24%
4.555
4.295
3 mois
11.94%
4.08
3.525
6 mois
49.01%
3.12
2.525
1 an
208.22%
1.49
1.07
3 ans
79.28%
2.5873
0.301
5 ans
39.75%
3.4376
0.301
10 ans
-6.64%
8.48
0.301
Calendrier économique
19 Septembre 2024 (heure UTC) Actuel Précédent Consensus
★★
13:00
United States
SEP
1.592
1.883
★
11:30
United States
SEP 17
4.700
4.965
★
11:30
United States
★
11:30
United States
SEP 17
4.690
4.990
★
11:30
United States
★
08:30
United States
Q2
-266800000000.000
-241000000000.000
-259000000000.000
★
10:30
United States
SEP 13
58000000000.000
40000000000.000
53000000000.000
★
10:30
United States
SEP 13
-96000000000.000
★★
10:00
United States
AUG
-2.500
1.500
★★
16:30
United States
SEP 18
7100000000000.000
7115000000000.000
★
08:30
United States
SEP 15
227500.000
231000.000
★
08:30
United States
SEP
34.000
24.000
★
16:30
United States
SEP 18
3217000000000.000
3360000000000.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:MREO240920C00001000 OCASPS Call American 100 1 EMLD 2024-09-20
O:MREO240920C00002000 OCASPS Call American 100 2 EMLD 2024-09-20
O:MREO240920C00003000 OCASPS Call American 100 3 EMLD 2024-09-20
O:MREO240920C00004000 OCASPS Call American 100 4 EMLD 2024-09-20
O:MREO240920C00005000 OCASPS Call American 100 5 EMLD 2024-09-20
O:MREO240920C00006000 OCASPS Call American 100 6 EMLD 2024-09-20
O:MREO240920C00007000 OCASPS Call American 100 7 EMLD 2024-09-20
O:MREO240920C00008000 OCASPS Call American 100 8 EMLD 2024-09-20
O:MREO240920P00001000 OPASPS Put American 100 1 EMLD 2024-09-20
O:MREO240920P00002000 OPASPS Put American 100 2 EMLD 2024-09-20
O:MREO240920P00003000 OPASPS Put American 100 3 EMLD 2024-09-20
O:MREO240920P00004000 OPASPS Put American 100 4 EMLD 2024-09-20
O:MREO240920P00005000 OPASPS Put American 100 5 EMLD 2024-09-20
O:MREO240920P00006000 OPASPS Put American 100 6 EMLD 2024-09-20
O:MREO240920P00007000 OPASPS Put American 100 7 EMLD 2024-09-20
O:MREO240920P00008000 OPASPS Put American 100 8 EMLD 2024-09-20
O:MREO240816C00006000 OCASPS Call American 100 6 EMLD 2024-08-16
O:MREO240816P00006000 OPASPS Put American 100 6 EMLD 2024-08-16
O:MREO240816C00000500 OCASPS Call American 100 0.5 EMLD 2024-08-16
O:MREO240816C00001000 OCASPS Call American 100 1 EMLD 2024-08-16
O:MREO240816C00001500 OCASPS Call American 100 1.5 EMLD 2024-08-16
O:MREO240816C00002000 OCASPS Call American 100 2 EMLD 2024-08-16
O:MREO240816C00003000 OCASPS Call American 100 3 EMLD 2024-08-16
O:MREO240816C00003500 OCASPS Call American 100 3.5 EMLD 2024-08-16
O:MREO240816C00004000 OCASPS Call American 100 4 EMLD 2024-08-16
O:MREO240816C00004500 OCASPS Call American 100 4.5 EMLD 2024-08-16
O:MREO240816C00005500 OCASPS Call American 100 5.5 EMLD 2024-08-16
O:MREO240816P00000500 OPASPS Put American 100 0.5 EMLD 2024-08-16
O:MREO240816P00001000 OPASPS Put American 100 1 EMLD 2024-08-16
O:MREO240816P00001500 OPASPS Put American 100 1.5 EMLD 2024-08-16
O:MREO240816P00002000 OPASPS Put American 100 2 EMLD 2024-08-16
O:MREO240816P00003000 OPASPS Put American 100 3 EMLD 2024-08-16
O:MREO240816P00003500 OPASPS Put American 100 3.5 EMLD 2024-08-16
O:MREO240816P00004000 OPASPS Put American 100 4 EMLD 2024-08-16
O:MREO240816P00004500 OPASPS Put American 100 4.5 EMLD 2024-08-16
O:MREO240816P00005500 OPASPS Put American 100 5.5 EMLD 2024-08-16
O:MREO240816C00002500 OCASPS Call American 100 2.5 EMLD 2024-08-16
O:MREO240816C00005000 OCASPS Call American 100 5 EMLD 2024-08-16
O:MREO240816C00007500 OCASPS Call American 100 7.5 EMLD 2024-08-16
O:MREO240816P00002500 OPASPS Put American 100 2.5 EMLD 2024-08-16
O:MREO240816P00005000 OPASPS Put American 100 5 EMLD 2024-08-16
O:MREO240816P00007500 OPASPS Put American 100 7.5 EMLD 2024-08-16
O:MREO240719C00002500 OCASPS Call American 100 2.5 EMLD 2024-07-19
O:MREO240719C00005000 OCASPS Call American 100 5 EMLD 2024-07-19
O:MREO240719C00007500 OCASPS Call American 100 7.5 EMLD 2024-07-19
O:MREO240719P00002500 OPASPS Put American 100 2.5 EMLD 2024-07-19
O:MREO240719P00005000 OPASPS Put American 100 5 EMLD 2024-07-19
O:MREO240719P00007500 OPASPS Put American 100 7.5 EMLD 2024-07-19
O:MREO240621C00002000 OCASPS Call American 100 2 EMLD 2024-06-21
O:MREO240621C00002500 OCASPS Call American 100 2.5 EMLD 2024-06-21
O:MREO240621C00003000 OCASPS Call American 100 3 EMLD 2024-06-21
O:MREO240621C00003500 OCASPS Call American 100 3.5 EMLD 2024-06-21
O:MREO240621C00004000 OCASPS Call American 100 4 EMLD 2024-06-21
O:MREO240621C00004500 OCASPS Call American 100 4.5 EMLD 2024-06-21
O:MREO240621C00005000 OCASPS Call American 100 5 EMLD 2024-06-21
O:MREO240621C00007500 OCASPS Call American 100 7.5 EMLD 2024-06-21
O:MREO240621P00002000 OPASPS Put American 100 2 EMLD 2024-06-21
O:MREO240621P00002500 OPASPS Put American 100 2.5 EMLD 2024-06-21
O:MREO240621P00003000 OPASPS Put American 100 3 EMLD 2024-06-21
O:MREO240621P00003500 OPASPS Put American 100 3.5 EMLD 2024-06-21
O:MREO240621P00004000 OPASPS Put American 100 4 EMLD 2024-06-21
O:MREO240621P00004500 OPASPS Put American 100 4.5 EMLD 2024-06-21
O:MREO240621P00005000 OPASPS Put American 100 5 EMLD 2024-06-21
O:MREO240621P00007500 OPASPS Put American 100 7.5 EMLD 2024-06-21
O:MREO240517C00000500 OCASPS Call American 100 0.5 EMLD 2024-05-17
O:MREO240517C00001000 OCASPS Call American 100 1 EMLD 2024-05-17
O:MREO240517C00001500 OCASPS Call American 100 1.5 EMLD 2024-05-17
O:MREO240517C00002000 OCASPS Call American 100 2 EMLD 2024-05-17
O:MREO240517C00003000 OCASPS Call American 100 3 EMLD 2024-05-17
O:MREO240517C00003500 OCASPS Call American 100 3.5 EMLD 2024-05-17
O:MREO240517C00004000 OCASPS Call American 100 4 EMLD 2024-05-17
O:MREO240517C00004500 OCASPS Call American 100 4.5 EMLD 2024-05-17
O:MREO240517C00005500 OCASPS Call American 100 5.5 EMLD 2024-05-17
O:MREO240517P00000500 OPASPS Put American 100 0.5 EMLD 2024-05-17
O:MREO240517P00001000 OPASPS Put American 100 1 EMLD 2024-05-17
O:MREO240517P00001500 OPASPS Put American 100 1.5 EMLD 2024-05-17
O:MREO240517P00002000 OPASPS Put American 100 2 EMLD 2024-05-17
O:MREO240517P00003000 OPASPS Put American 100 3 EMLD 2024-05-17
O:MREO240517P00003500 OPASPS Put American 100 3.5 EMLD 2024-05-17
O:MREO240517P00004000 OPASPS Put American 100 4 EMLD 2024-05-17
O:MREO240517P00004500 OPASPS Put American 100 4.5 EMLD 2024-05-17
O:MREO240517P00005500 OPASPS Put American 100 5.5 EMLD 2024-05-17
O:MREO240517C00002500 OCASPS Call American 100 2.5 EMLD 2024-05-17
O:MREO240517C00005000 OCASPS Call American 100 5 EMLD 2024-05-17
O:MREO240517C00007500 OCASPS Call American 100 7.5 EMLD 2024-05-17
O:MREO240517P00002500 OPASPS Put American 100 2.5 EMLD 2024-05-17
O:MREO240517P00005000 OPASPS Put American 100 5 EMLD 2024-05-17
O:MREO240517P00007500 OPASPS Put American 100 7.5 EMLD 2024-05-17
O:MREO240419C00001500 OCASPS Call American 100 1.5 EMLD 2024-04-19
O:MREO240419C00002500 OCASPS Call American 100 2.5 EMLD 2024-04-19
O:MREO240419C00003000 OCASPS Call American 100 3 EMLD 2024-04-19
O:MREO240419C00003500 OCASPS Call American 100 3.5 EMLD 2024-04-19
O:MREO240419C00004000 OCASPS Call American 100 4 EMLD 2024-04-19
O:MREO240419C00004500 OCASPS Call American 100 4.5 EMLD 2024-04-19
O:MREO240419C00005000 OCASPS Call American 100 5 EMLD 2024-04-19
O:MREO240419C00005500 OCASPS Call American 100 5.5 EMLD 2024-04-19
O:MREO240419C00007500 OCASPS Call American 100 7.5 EMLD 2024-04-19
O:MREO240419P00001500 OPASPS Put American 100 1.5 EMLD 2024-04-19
O:MREO240419P00002500 OPASPS Put American 100 2.5 EMLD 2024-04-19
O:MREO240419P00003000 OPASPS Put American 100 3 EMLD 2024-04-19
O:MREO240419P00003500 OPASPS Put American 100 3.5 EMLD 2024-04-19
O:MREO240419P00004000 OPASPS Put American 100 4 EMLD 2024-04-19
O:MREO240419P00004500 OPASPS Put American 100 4.5 EMLD 2024-04-19
O:MREO240419P00005000 OPASPS Put American 100 5 EMLD 2024-04-19
O:MREO240419P00005500 OPASPS Put American 100 5.5 EMLD 2024-04-19
O:MREO240419P00007500 OPASPS Put American 100 7.5 EMLD 2024-04-19
O:MREO240315C00000500 OCASPS Call American 100 0.5 EMLD 2024-03-15
O:MREO240315C00001000 OCASPS Call American 100 1 EMLD 2024-03-15
O:MREO240315C00001500 OCASPS Call American 100 1.5 EMLD 2024-03-15
O:MREO240315C00002000 OCASPS Call American 100 2 EMLD 2024-03-15
O:MREO240315C00003000 OCASPS Call American 100 3 EMLD 2024-03-15
O:MREO240315C00003500 OCASPS Call American 100 3.5 EMLD 2024-03-15
O:MREO240315C00004000 OCASPS Call American 100 4 EMLD 2024-03-15
O:MREO240315C00004500 OCASPS Call American 100 4.5 EMLD 2024-03-15
O:MREO240315C00005500 OCASPS Call American 100 5.5 EMLD 2024-03-15
O:MREO240315P00000500 OPASPS Put American 100 0.5 EMLD 2024-03-15
O:MREO240315P00001000 OPASPS Put American 100 1 EMLD 2024-03-15
O:MREO240315P00001500 OPASPS Put American 100 1.5 EMLD 2024-03-15
O:MREO240315P00002000 OPASPS Put American 100 2 EMLD 2024-03-15
O:MREO240315P00003000 OPASPS Put American 100 3 EMLD 2024-03-15
O:MREO240315P00003500 OPASPS Put American 100 3.5 EMLD 2024-03-15
O:MREO240315P00004000 OPASPS Put American 100 4 EMLD 2024-03-15
O:MREO240315P00004500 OPASPS Put American 100 4.5 EMLD 2024-03-15
O:MREO240315P00005500 OPASPS Put American 100 5.5 EMLD 2024-03-15
O:MREO240315C00002500 OCASPS Call American 100 2.5 EMLD 2024-03-15
O:MREO240315C00005000 OCASPS Call American 100 5 EMLD 2024-03-15
O:MREO240315C00007500 OCASPS Call American 100 7.5 EMLD 2024-03-15
O:MREO240315P00002500 OPASPS Put American 100 2.5 EMLD 2024-03-15
O:MREO240315P00005000 OPASPS Put American 100 5 EMLD 2024-03-15
O:MREO240315P00007500 OPASPS Put American 100 7.5 EMLD 2024-03-15
O:MREO240216C00002500 OCASPS Call American 100 2.5 EMLD 2024-02-16
O:MREO240216C00005000 OCASPS Call American 100 5 EMLD 2024-02-16
O:MREO240216C00007500 OCASPS Call American 100 7.5 EMLD 2024-02-16
O:MREO240216P00002500 OPASPS Put American 100 2.5 EMLD 2024-02-16
O:MREO240216P00005000 OPASPS Put American 100 5 EMLD 2024-02-16
O:MREO240216P00007500 OPASPS Put American 100 7.5 EMLD 2024-02-16
O:MREO240119C00002500 OCASPS Call American 100 2.5 EMLD 2024-01-19
O:MREO240119C00005000 OCASPS Call American 100 5 EMLD 2024-01-19
O:MREO240119C00007500 OCASPS Call American 100 7.5 EMLD 2024-01-19
O:MREO240119P00002500 OPASPS Put American 100 2.5 EMLD 2024-01-19
O:MREO240119P00005000 OPASPS Put American 100 5 EMLD 2024-01-19
O:MREO240119P00007500 OPASPS Put American 100 7.5 EMLD 2024-01-19
O:MREO231215C00002500 OCASPS Call American 100 2.5 EMLD 2023-12-15
O:MREO231215C00005000 OCASPS Call American 100 5 EMLD 2023-12-15
O:MREO231215C00007500 OCASPS Call American 100 7.5 EMLD 2023-12-15
O:MREO231215P00002500 OPASPS Put American 100 2.5 EMLD 2023-12-15
O:MREO231215P00005000 OPASPS Put American 100 5 EMLD 2023-12-15
O:MREO231215P00007500 OPASPS Put American 100 7.5 EMLD 2023-12-15
O:MREO231117C00002500 OCASPS Call American 100 2.5 EMLD 2023-11-17
O:MREO231117C00005000 OCASPS Call American 100 5 EMLD 2023-11-17
O:MREO231117C00007500 OCASPS Call American 100 7.5 EMLD 2023-11-17
O:MREO231117P00002500 OPASPS Put American 100 2.5 EMLD 2023-11-17
O:MREO231117P00005000 OPASPS Put American 100 5 EMLD 2023-11-17
O:MREO231117P00007500 OPASPS Put American 100 7.5 EMLD 2023-11-17
O:MREO231020C00002500 OCASPS Call American 100 2.5 EMLD 2023-10-20
O:MREO231020C00005000 OCASPS Call American 100 5 EMLD 2023-10-20
O:MREO231020C00007500 OCASPS Call American 100 7.5 EMLD 2023-10-20
O:MREO231020P00002500 OPASPS Put American 100 2.5 EMLD 2023-10-20
O:MREO231020P00005000 OPASPS Put American 100 5 EMLD 2023-10-20
O:MREO231020P00007500 OPASPS Put American 100 7.5 EMLD 2023-10-20
O:MREO230915C00002500 OCASPS Call American 100 2.5 EMLD 2023-09-15
O:MREO230915C00005000 OCASPS Call American 100 5 EMLD 2023-09-15
O:MREO230915C00007500 OCASPS Call American 100 7.5 EMLD 2023-09-15
O:MREO230915P00002500 OPASPS Put American 100 2.5 EMLD 2023-09-15
O:MREO230915P00005000 OPASPS Put American 100 5 EMLD 2023-09-15
O:MREO230915P00007500 OPASPS Put American 100 7.5 EMLD 2023-09-15
O:MREO230818C00002500 OCASPS Call American 100 2.5 EMLD 2023-08-18
O:MREO230818C00005000 OCASPS Call American 100 5 EMLD 2023-08-18
O:MREO230818C00007500 OCASPS Call American 100 7.5 EMLD 2023-08-18
O:MREO230818P00002500 OPASPS Put American 100 2.5 EMLD 2023-08-18
O:MREO230818P00005000 OPASPS Put American 100 5 EMLD 2023-08-18
O:MREO230818P00007500 OPASPS Put American 100 7.5 EMLD 2023-08-18
Flux d'actualités
News OKX Ventures
OKX Ventures and Aptos Foundation Announce First Four Projects Selected for the Ankaa Accelerator Program
OKX Ventures and Aptos Foundation have selected four projects for the Ankaa Accelerator Program, which aims to support the growth of the Aptos ecosystem and Web3 adoption. The selected projects include Mizu, Playsout, Luckey, and Mereo, which demonstrate significant potential to contribute to the Web3 ecosystem.
GlobeNewswire Inc. • Il y a 5 heures
News Mereo BioPharma
Mereo BioPharma publie ses résultats financiers du deuxième trimestre 2024 et fait le point sur la situation de l'entreprise
Mereo BioPharma a annoncé des résultats positifs à 14 mois de la partie phase 2 de l'étude de phase 2/3 Orbit en cours pour le setrusumab dans l'ostéogenèse imparfaite, démontrant une réduction de 67% des taux de fractures annualisés. La société a également fait le point sur son programme alvelestat pour les maladies pulmonaires associées au déficit en alpha-1-antitrypsine et sur sa situation financière, avec 87,4 millions de dollars de liquidités qui devraient permettre de financer les opérations jusqu'en 2027.
GlobeNewswire Inc. • Il y a 1 mois
Stocks Financing Agreements
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate purposes. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions.
GlobeNewswire Inc. • Il y a 3 mois
Calendar Calendar of Events
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST.
GlobeNewswire Inc. • Il y a 3 mois
News News
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research • Il y a 5 mois
Calendar Calendar of Events
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST.
GlobeNewswire Inc. • Il y a 5 mois
stocks Earnings Releases and Operating Results
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively
GlobeNewswire Inc. • Il y a 5 mois
Stocks Earnings Releases and Operating Results
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively
GlobeNewswire Inc. • Il y a 5 mois
News Product / Services Announcement
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024
GlobeNewswire Inc. • Il y a 8 mois
News Product / Services Announcement
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.
GlobeNewswire Inc. • Il y a 11 mois
Voir tous
Actualités liées
Dernières actualités

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT